Medi-Caps Limited (523144) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Medi-Caps Limited ₹34.62, price ₹26.66, upside +29.9%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Medi-Caps Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹21.86 – ₹86.35 · fair‑value band ₹22.85 – ₹43.28 · the ₹26.66 price screens below the ₹34.62 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Medi-Caps in your weekly email
Every Wednesday you see whether Medi-Caps is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Medi-Caps Limited manufactures and sells empty hard gelatin capsule shells in India. It offers halal gelatin, liquid fill, sodium lauryl sulfate free, and preservative free capsules. The company was incorporated in 1983 and is based in Indore, India.
Stock analysis
Medi-Caps Limited (523144) currently trades at ₹26.66, while our model-based Fair Value estimate is ₹34.62, implying the stock looks roughly 23.0% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: ₹22.85 (bear) to ₹43.28 (bull), the price of ₹26.66 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Health Care sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Medi-Caps Limited reported revenue of ₹124M in FY2026 versus ₹699M in FY2022, a compound −35.1%/yr. Reported net income was −₹30.4M in FY2026.
Key figures
Market cap ₹332M (≈ $3.5M) · P/E ratio 29.3 · P/S ratio 0.66 · EPS (TTM) ₹1.10 · Net margin −24.5% · Return on assets (EBIT) −1.0% · Operating margin −9.7% · Revenue growth (YoY) −20.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 34% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Health Care peers we cover trades at −40% fair-value upside, at 30%, 523144 screens cheaper than that median.
Fair Value models
Bear ₹22.85Fair Value ₹34.62Bull ₹43.28
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹0.5590 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−51.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−36.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−26.4%
Start year 2021 (pandemic). Over 10 years: −11.7% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.8%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.3% (2021) → −90.5% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 53 stocks
Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score46 · Below median
Fair Value upside+29.9% · Above median
Profitability
Return on assets−0.2% · Bottom 25%
Net margin (TTM)−10.4% · Bottom 25%
Operating margin (TTM)−9.7% · Bottom 25%
Growth and dividend
Revenue growth−20.9% · Bottom 25%
Dividend yield (TTM)0.0% · Bottom 25%
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Medi-Caps Limited Fair Value". https://www.fairvalue-calculator.com/stock/523144
Frequently asked questions
Is Medi-Caps Limited (523144) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹34.62 versus a price of ₹26.66, about +30% upside (undervalued).
What is the fair value of 523144?
Our model-based fair value for Medi-Caps Limited is ₹34.62 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹26.66.
What is the quality score of 523144?
Medi-Caps Limited has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medi-Caps Limited (523144)?
Our model-based price target is the fair value of ₹34.62 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario ₹22.85, optimistic scenario ₹43.28. It is a calculation from audited fundamentals, not an analyst target.
What is the Medi-Caps Limited stock forecast for 2026?
Our models put fair value at ₹34.62, about +30% upside versus a price of ₹26.66 (undervalued). Cautious scenario ₹22.85, optimistic scenario ₹43.28. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Medi-Caps Limited (523144)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medi-Caps Limited it is ₹34.62 per share (as of Sep 24, 2026), against a price of ₹26.66. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Medi-Caps Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 523144 trades below its calculated fair value: price ₹26.66, fair value ₹34.62, a gap of about +30% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 523144?
No. The price is what the market pays today (₹26.66); the fair value is what the company's own numbers justify (₹34.62). For Medi-Caps Limited the two are ₹7.96 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medi-Caps Limited worth?
The market values Medi-Caps Limited at about ₹332M (market capitalisation, as of Sep 24, 2026). Per share that is ₹26.66; our models calculate a fair value of ₹34.62 per share.
What do the bullish and bearish scenarios say about 523144?
Our models span a range for Medi-Caps Limited: cautious scenario ₹22.85, base ₹34.62, optimistic ₹43.28 per share (as of Sep 24, 2026, price ₹26.66). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 523144?
Medi-Caps Limited trades at a price-to-earnings ratio of 29.3 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹34.62 is built from several models across several years.
How far is 523144 from its 52-week high?
Medi-Caps Limited trades at ₹26.66, about 34% below its 52-week high of ₹40.42 and 22% above the low of ₹21.86 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹34.62 is for.
Which stocks are comparable to Medi-Caps Limited?
From the same area (Health Care) we also value Caregen Co, ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medi-Caps Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹26.66, calculated fair value ₹34.62 (+30%), Quality Score 44/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 523144 calculated?
We run Medi-Caps Limited through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹34.62, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Medi-Caps Limited currently trades 23 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medi-Caps Limited (523144)?
The closing price on Oct 1, 2026 was ₹26.66. Our model-based fair value is ₹34.62, about +30% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medi-Caps Limited right now?
A fairly wide model range (₹22.85 to ₹43.28) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Medi-Caps Limited
How large is the market capitalisation of Medi-Caps Limited (523144)?
The market capitalisation of Medi-Caps Limited is ₹332M (≈ $3.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medi-Caps Limited (523144)?
The price-to-sales ratio of Medi-Caps Limited is 0.66 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medi-Caps Limited (523144)?
Earnings per share at Medi-Caps Limited are ₹1.10 (price ÷ EPS = P/E 29.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medi-Caps Limited (523144)?
The net margin of Medi-Caps Limited is −24.5% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Medi-Caps Limited (523144)?
On an EBIT basis the return on assets of Medi-Caps Limited is −1.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medi-Caps Limited (523144)?
The operating margin of Medi-Caps Limited is −9.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medi-Caps Limited (523144)?
Revenue at Medi-Caps Limited is growing −20.9% versus a year earlier (3y avg −36.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Medi-Caps Limited (523144) generate?
The free cash flow of Medi-Caps Limited is −₹78.7M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Medi-Caps Limited (523144) carry?
The net debt of Medi-Caps Limited is ₹619K (fiscal year 2020). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Medi-Caps Limited in the live analysis
One click puts Medi-Caps Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
